Fisher & Paykel Healthcare lifts profit 24% on hospital and homecare growth

Fisher & Paykel Healthcare Corporation Limited ( (NZ:FPH) ) has shared an update.

Fisher & Paykel Healthcare reported a robust 2026 financial year, with operating revenue rising 14% to $2.31 billion and net profit after tax climbing 24% to $468.5 million, underpinned by an 18% revenue increase in its Hospital product group and 8% growth in Homecare. Strength in hospital consumables despite subdued seasonal respiratory admissions, improving gross margins, a 10% of revenue commitment to R&D and expanded campus capacity, alongside a 22% higher annual dividend and guidance for further revenue and profit gains in 2027, all point to sustained operational momentum and a reinforced competitive position in global respiratory care markets.

The most recent analyst rating on (NZ:FPH) stock is a Buy with a N$33.50 price target. To see the full list of analyst forecasts on Fisher & Paykel Healthcare Corporation Limited stock, see the NZ:FPH Stock Forecast page.

More about Fisher & Paykel Healthcare Corporation Limited

Fisher & Paykel Healthcare is a New Zealand-based medical technology company that designs, manufactures and markets products and systems for acute and chronic respiratory care, surgical care and the treatment of obstructive sleep apnea. The company sells its hospital and homecare respiratory therapies in more than 120 countries, giving it a broad global footprint in both clinical and home settings.

YTD Price Performance: -9.67%

Average Trading Volume: 508,988

Technical Sentiment Signal: Hold

Current Market Cap: N$20.03B

For an in-depth examination of FPH stock, go to TipRanks’ Overview page.